NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.
Merck will present late-breaking clinical data from its cardio-pulmonary pipeline at ACC.26, including positive Phase 3 results for enlicitide, an investigational oral PCSK9 inhibitor, and Phase 2 data for WINREVAIR in heart failure patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07752758 |
Ezetimibe for Arrhythmia Recurrence After AF Ablation |
NOT_YET_RECRUITING | PHASE4 |
| NCT07474649 |
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events |
NOT_YET_RECRUITING | PHASE3 |
| NCT06686615 |
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia |
RECRUITING |
